A 12‐Month Randomized Controlled Study of the Aldose Reductase Inhibitor Ponalrestat in Patients with Chronic Symptomatic Diabetic Neuropathy

Diabetic Medicine

Volumn 9, Issue 5, 1992, Pages 463-468

  Krentz, A J ^a   Honigsberger, L ^b   Ellis, S H ^c   Hardman, M ^c   Nattrass, M ^a  

^a GENERAL HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

Aldose reductase inhibitor; Clinical trials; Diabetic neuropathy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; INSULIN; PLACEBO; PONALRESTAT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; HUMAN; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACTION POTENTIALS; ADULT; ALDEHYDE REDUCTASE; ANALYSIS OF VARIANCE; BLOOD PRESSURE; COMPARATIVE STUDY; DIABETIC NEUROPATHIES; HUMAN; MIDDLE AGE; NEURAL CONDUCTION; NEURONS, AFFERENT; PERIPHERAL NERVES; PHTHALAZINES; SUPPORT, NON-U.S. GOV'T;

EID: 0026631063     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.1992.tb01818.x     Document Type: Article

References (30)

1. Diabetic neuropathy: Clinical aspects
2. Diabetic peripheral neuropathies
3. Diabetic neuropathy
4. Does a common mechanism induce the diverse complications of diabetes?
5. Are disturbances of sorbitol, phosphoinositide, and Na+‐K+‐ATPase regulation involved in pathogenesis of diabetic neuropathy?
6. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications
7. Aldose reductase inhibitors and diabetic complications
8. Aldose reductase inhibitors
9. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients
10. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy
11. Clinical and neurophysiological studies with the aldose reductase inhibitor, Sorbinil, in symptomatic diabetic neuropathy
12. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24‐week controlled trial
13. Regeneration and repair of myelinated nerve fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil
14. A multicentre trial of the aldose‐reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy
15. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic neuropathy
16. The natural history of painful diabetic neuropathy: a four year study
17. Selection of patients with symptomatic diabetic neuropathy for clinical trials
18. Electrophysiological studies in diabetic neuropathy
19. Variability of three standard neurophysiological techniques in established symptomatic diabetic neuropathy
20. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non‐diabetic subjects
21. Respiratory influence on heart rate in diabetes mellitus
22. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy
23. Electrophysiological testing for diabetic neuropathy
24. A study of peripheral diabetic neuropathy. The application of age‐related reference values
25. Report and recommendations of the San Antonio conference on diabetic neuropathy
26. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy
27. Detection, characterization and staging of polyneuropathy: assessed in diabetics
28. Capillary number and percentage closed in human diabetic sural nerve
29. Microangiopathy in human diabetic neuropathy
30. Red cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin‐dependent diabetic subjects